A Right To Live Inc, Aka Accelerate Progress

Causes: Cancer, Health

Mission: We are focused on "Accelerating Access Through Better Science" and approach our mission from both a policy perspective and a direct research perspective. Tremendous work has been done to advance our understanding of the diseases we call cancer, not to mention many other life-threatening diseases. Progress in understanding the biological causes and genetic pathways that can lead to cancer and other life-threatening diseases has been substantial. Where we have fallen short is in translating those gains in knowledge into meaningful patient benefits. Failures and inefficiencies in our approaches to developing and using new medical treatments contribute to the needless suffering and death of hundreds of thousands of patients each year. With that as background, then, Accelerate Progress seeks to identify and then implement improvements to those research & development, regulatory, and treatment systems that show the most promise to accelerate our progress against cancer and other such diseases. To further our mission, in addition to identifying and implementing systems improvements noted above, Accelerate Progress will also fund direct research efforts, particularly in the areas of adaptive trial design, Bayesian and other modern statistical analyses, biomarker identification and validation, and other related diagnostics research, focusing on areas not currently well served by for-profit organizations or other non-profits. We will provide expertise, direction, communication, and passion for both patients and progress. Accelerate Progress is focused on accelerating access to promising and potentially lifesaving new therapeutics through the broad adoption and use of better science. Better science to Accelerate Progress means better trial designs, more use of advanced statistical analysis methods, better communication and collaboration between stakeholders, greater transparency in all aspects of the development and regulatory review processes, validation and increased use of biomarkers and related diagnostics within the development process, and other similar improvements.